Skip to content
HowShorted

Evofem Biosciences, Inc. short interest in 2020

In 2020, Evofem Biosciences, Inc.'s disclosed short interest ran from 1.70% of shares outstanding on 15 Jan 2020 to 14.38% on 31 Dec 2020, a change of +12.68 percentage points. The year's high was 16.06% on 15 Sep 2020 and its low 1.70% on 15 Jan 2020, averaging 6.67% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 17.04 days on 14 Feb 2020. Full history: Evofem Biosciences, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for Evofem Biosciences, Inc. in 2020

2020 in figures

Start of year
1.70% (15 Jan 2020)
End of year
14.38% (31 Dec 2020)
Change
+12.68 pp
High
16.06% (15 Sep 2020)
Low
1.70% (15 Jan 2020)
Average
6.67%
Highest days to cover
17.04 (14 Feb 2020)
SEC filings marked
8

Every report in 2020

Evofem Biosciences, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20201.70%13.94
31 Jan 20201.85%16.80
14 Feb 20202.03%17.04
28 Feb 20202.17%7.34
13 Mar 20202.59%11.4010-K filed, results (8-K)
31 Mar 20202.64%7.85
15 Apr 20203.22%13.48
30 Apr 20204.31%8.79
15 May 20205.18%8.0310-Q filed, results (8-K)
29 May 20207.71%1.00
15 Jun 20203.76%1.00
30 Jun 20204.97%1.00
15 Jul 20206.93%1.12
31 Jul 20204.67%1.85
14 Aug 20204.51%1.1710-Q filed, results (8-K)
31 Aug 20206.69%1.73
15 Sep 202016.06%1.24
30 Sep 202014.52%2.90
15 Oct 202010.79%3.43
30 Oct 20209.16%5.96
13 Nov 20209.62%5.0510-Q filed, results (8-K)
30 Nov 20208.92%3.95
15 Dec 202011.78%3.82
31 Dec 202014.38%3.29

See also: Evofem Biosciences, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.